-

Media Advisory: Ribbon-cutting Ceremony for new Zoetis facility in Durham, N.C., to expand diagnostics R&D and engineering capabilities and bring more jobs to Durham

DURHAM, N.C.--(BUSINESS WIRE)--Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis’ engineering and diagnostics work including device reliability testing. The new building features more than 78,000 square feet including 23,000 square feet of total lab space allotted for a biodevice engineering lab, biodevice science lab, diagnostics engineering lab and diagnostics engineering lab space. Zoetis employs approximately 200 people at its site in Durham, more than half of whom are dedicated to the company’s R&D work.

The event will take place on August 24 at 11:00 AM ET at the following location:

Zoetis 
1050 Swabia Court 
Durham, NC 27703

During the outdoor ceremony, North Carolina State Representative Zack Hawkins and key company leaders, including Zoetis CEO Kristin Peck and President of Research and Development Rob Polzer, will be present to share insights into the new facility, potential impact on animal health and what the expansion brings to the local Durham community.

The program for the event includes:

  • Welcome address by Kristin Peck, CEO of Zoetis
  • Remarks by Zack Hawkins on the significance of the new facility for the community
  • Photo opportunity with Zack Hawkins, Kristin Peck and other company leaders outside the facility; interior site images will be available on request (access to facility is restricted to maintain a sterile environment)
  • Exclusive Q&A session with Rob Polzer

Registration information:

Please register to attend by emailing: christina.lood@zoetis.com.

We kindly request that media representatives check in and present press credentials at site security upon arrival.

A press release with event details and additional images will be available following the live event.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.

Contacts

Media:
Christina Lood
973-822-7249
christina.lood@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Versions
$Cashtags

Contacts

Media:
Christina Lood
973-822-7249
christina.lood@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture...

Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well...

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. “The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives and communities....
Back to Newsroom